At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,600 enrolled
Drug / intervention
EuCorVac-19 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Observer-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Immunogenicity and Safety of a Preventive COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older
In Brief
A Phase 3 clinical trial evaluating EuCorVac-19 and ChAdOx1 nCoV-19 for COVID-19. Completed, enrolled 2,600 participants across 1 site.
Detailed Summary
This is a phase III, randomized, observer-blind, active-controlled, parallel group, multi-center study to compare the immunogenicity and safety of a preventive COVID-19 vaccine EuCorVac-19 to ChAdOx1 in healthy adults aged 18 years and older
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesPhilippines
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartOct 2022
First PostedOct 2022
Primary CompletionJun 2023
Study CompletionFeb 2024
TodayJul 2026
First PostedOct 10, 2022
Enrollment StartOct 1, 2022
Primary CompletionJun 23, 2023
Study CompletionFeb 9, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 3.7 years ago
Interventions
EuCorVac-19biological
COVID-19 vaccine
ChAdOx1 nCoV-19biological
COVID-19 vaccine